Dietary Factors and Disfluency: A Look Into Food Allergies and Other Environmental Triggers Associated With Variations in Severity of Vocal Cord Tension.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02547051|
Recruitment Status : Not yet recruiting
First Posted : September 11, 2015
Last Update Posted : October 11, 2017
|Condition or disease||Intervention/treatment||Phase|
|Vocal Cord Tension Dysfluency Developmental||Other: Food Allergy Testing and Elimination Diet||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dietary Factors and Disfluency. A Look Into Causes and Variations in Severity of Disfluency in Regards to Vocal Cord Tension.|
|Estimated Study Start Date :||January 2018|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||February 2022|
Experimental: Food allergy and vocal cord tension
To determine if dietary allergen responses and frequency and severity of vocal cord tension.
Other: Food Allergy Testing and Elimination Diet
Food allergy testing and elimination diet
- Dietary Factors and Disfluency: Variations in Severity of Vocal Cord tension [ Time Frame: 1 Year ]
Initial fluency samples are taken prior to treatment protocol of study.
Food sensitivity panel will be assessed for potential allergans. Allergan responses are graded from 0 being no response to food allergen to 3 being the strongest response and subsequent removal of sensitive allergan from diet. Speech sample and disfluency severity will be evaluated qualitatively again via the SSI-3 on repeat office visit at fixed interval scale. Erickson S-24 repeated at end of study and final conclusions made.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02547051
|Contact: Yohan R, Medical Doctorfirstname.lastname@example.org|
|United States, Texas|
|Houston, Texas, United States, 77007|